Appeals court grants stay on Praluent injunction

A federal appeals court granted a motion to stay a permanent injunction blocking U.S. sales of Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Last month, a district court judge granted the injunction to Amgen Inc. (NASDAQ:AMGN), which markets competing PCSK9 inhibitor Repatha evolocumab, in a patent infringement suit (see BioCentury Extra, Jan. 5).

The injunction would have required Sanofi and Regeneron to halt U.S. sales of Praluent on Feb. 21. Sales will now continue during the appeal process...